Summary
Gilead Sciences, Inc. (GILD) announced on November 21, 2011, its entry into a definitive Agreement and Plan of Merger to acquire Pharmasset, Inc. This strategic move involves a tender offer for all outstanding Pharmasset common stock at a price of $137.00 per share, in cash. Following the tender offer, Gilead intends to complete a merger, making Pharmasset a wholly-owned subsidiary. The acquisition is expected to significantly bolster Gilead's pipeline, particularly in the area of hepatitis C (HCV) antivirals, as Pharmasset was known for its promising investigational compounds. Investors should note that the transaction is subject to customary closing conditions, including the satisfaction of the Minimum Tender Condition (at least a majority of outstanding shares) and antitrust approvals.
Key Highlights
- 1Gilead Sciences to acquire Pharmasset, Inc. for $137.00 per share in cash.
- 2The acquisition is structured as a tender offer followed by a merger.
- 3Pharmasset is a key player in the development of hepatitis C (HCV) antiviral treatments.
- 4The deal aims to significantly enhance Gilead's pipeline in the antiviral space.
- 5The transaction is contingent on a minimum tender of shares, representing at least a majority of Pharmasset's outstanding common stock.
- 6Antitrust clearance, including under the Hart-Scott-Rodino Act, is a required condition for closing.